Clinical Trial

A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)

Name: A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA) — clinical trial record (NCT06847607)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Record status

This record was last updated February 26, 2025 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.

Summary

To evaluate the efficacy and safety of ipecopam in the treatment of refractory/relapsed AIHA.

Trial Details

NCT Number	NCT06847607
Lead Sponsor	Bing Han
Conditions	AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia
Enrollment	20 participants
Start Date	2025-03-01
Primary Completion	2025-10-30 (estimated)
Study Completion	2026-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-02-26